Nurix Therapeutics (NRIX) Return on Sales (2020 - 2025)
Historic Return on Sales for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 5.76%.
- Nurix Therapeutics' Return on Sales fell 13500.0% to 5.76% in Q4 2025 from the same period last year, while for Nov 2025 it was 3.15%, marking a year-over-year increase of 4000.0%. This contributed to the annual value of 3.15% for FY2025, which is 4000.0% up from last year.
- Nurix Therapeutics' Return on Sales amounted to 5.76% in Q4 2025, which was down 13500.0% from 10.95% recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Return on Sales registered a high of 0.79% during Q2 2023, and its lowest value of 10.95% during Q3 2025.
- For the 5-year period, Nurix Therapeutics' Return on Sales averaged around 4.0%, with its median value being 3.8% (2021).
- Per our database at Business Quant, Nurix Therapeutics' Return on Sales skyrocketed by 41200bps in 2023 and then tumbled by -70600bps in 2025.
- Over the past 5 years, Nurix Therapeutics' Return on Sales (Quarter) stood at 5.1% in 2021, then plummeted by -35bps to 6.89% in 2022, then skyrocketed by 60bps to 2.77% in 2023, then crashed by -59bps to 4.41% in 2024, then plummeted by -31bps to 5.76% in 2025.
- Its last three reported values are 5.76% in Q4 2025, 10.95% for Q3 2025, and 0.99% during Q2 2025.